Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E38.46 EPS (ttm)1.82 Insider Own0.50% Shs Outstand1.54B Perf Week6.90%
Market Cap107.65B Forward P/E11.76 EPS next Y5.95 Insider Trans4.57% Shs Float1.53B Perf Month-8.54%
Income3.07B PEG1.16 EPS next Q0.84 Inst Own93.90% Short Float6.00% Perf Quarter-10.14%
Sales11.20B P/S9.61 EPS this Y10.40% Inst Trans0.05% Short Ratio5.88 Perf Half Y6.63%
Book/sh7.41 P/B9.45 EPS next Y49.72% ROA13.70% Target Price98.25 Perf Year37.63%
Cash/sh1.39 P/C50.50 EPS next 5Y33.28% ROE28.30% 52W Range46.70 - 84.88 Perf YTD-6.79%
Dividend- P/FCF36.94 EPS past 5Y11.90% ROI18.70% 52W High-17.53% Beta0.69
Dividend %- Quick Ratio0.80 Sales past 5Y16.00% Gross Margin74.50% 52W Low49.89% ATR2.94
Employees6100 Current Ratio1.10 Sales Q/Q20.50% Oper. Margin40.40% RSI (14)43.15 Volatility4.50% 4.31%
OptionableYes Debt/Eq0.58 EPS Q/Q142.10% Profit Margin27.40% Rel Volume1.12 Prev Close69.28
ShortableYes LT Debt/Eq0.35 EarningsApr 22 Payout0.00% Avg Volume15.62M Price70.00
Recom1.80 SMA20-1.33% SMA50-8.85% SMA2001.04% Volume17,526,520 Change1.04%
21-Feb-14Reiterated Barclays Overweight $90 → $95
10-Feb-14Reiterated Argus Buy $84 → $90
05-Feb-14Reiterated RBC Capital Mkts Outperform $90 → $96
05-Feb-14Reiterated Needham Buy $85 → $95
05-Feb-14Reiterated Maxim Group Buy $98 → $101
04-Feb-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
28-Jan-14Reiterated Deutsche Bank Buy $95 → $132
06-Jan-14Reiterated UBS Buy $80 → $102
02-Jan-14Reiterated Maxim Group Buy $89 → $98
20-Dec-13Reiterated RBC Capital Mkts Outperform $80 → $90
01-Nov-13Reiterated Argus Buy $70 → $84
30-Oct-13Reiterated RBC Capital Mkts Outperform $72 → $80
30-Oct-13Reiterated Barclays Overweight $68 → $74
26-Jul-13Reiterated Stifel Buy $65 → $75
26-Jul-13Reiterated RBC Capital Mkts Outperform $62 → $72
26-Jul-13Reiterated Barclays Overweight $65 → $68
26-Jul-13Downgrade Robert W. Baird Outperform → Neutral $55 → $65
13-Jun-13Upgrade Argus Hold → Buy
17-May-13Reiterated UBS Buy $63 → $67
03-May-13Reiterated Oppenheimer Outperform $59 → $61
17-Apr-14 05:26PM  If This Biotech Drops Much Further I'm Going to Buy It! at Motley Fool
02:32PM  Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead at Motley Fool
01:03PM  Today's Top Performers In Drugs at TheStreet
12:30PM  Midday movers: Weibo, Sabre, Goldman Sachs & More at CNBC
12:25PM  [video] Voice of CNBC reads FMHR tweets at CNBC
11:43AM  England agrees funding for Gilead hepatitis C drug Reuters
11:42AM  Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides at Motley Fool
11:18AM  UnitedHealth's 1Q profit tumbles 8 percent AP
09:18AM  Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings at TheStreet
07:38AM  Ready For A Rebound? Gilead's $1000 Pill at Seeking Alpha
06:46AM  3 Stocks to Get on Your Watchlist at Motley Fool
16-Apr-14 02:54PM  Johnson and Johnson Earnings Surprises With Blockbuster Potential at Motley Fool
01:35PM  Gilead Sciences May See A Healthy Earnings Beat at Seeking Alpha
09:01AM  [video] Cramer's mechanics of the market at CNBC
08:50AM  Gilead: This Baby Has Been Thrown Away With The Bathwater at Seeking Alpha
06:50AM  Why Gilead Sciences Inc. (GILD) Stock Might be a Great Pick Zacks
15-Apr-14 06:32PM  How Much Has Merck Shaken Up the Hepatitis C Race? at Motley Fool
05:40PM  Bristol-Myers Seeks Approval for HIV Combo Drug Zacks
05:00PM  Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 Business Wire
04:23PM  Nasdaq rides biggest trading rollercoaster in five years at CNBC
02:12PM  Biotech Bubble Bust: 2 Ways to Win at Motley Fool
02:08PM  A Wall Street Transcript Interview with Kenneth M. Conrad, Ph.D., CFA, a Portfolio Manager at BMO Global Asset Management for the BMO Custom Quantitative Solutions Group: Removing Emotion from Creating an Equity Yield Portfolio Wall Street Transcript
02:03PM  Nasdaq edges toward psychological 10 percent correction at CNBC
02:03PM  Capitulation or correction? Nasdaq nears 10% drop at CNBC
12:40PM  [video] Love biotech on correction: Trader at CNBC
12:37PM  [video] Top biotech analyst forecasts bottom at CNBC
12:19PM  Coca-Cola up on earnings; Best Buy tops S&P 500 losers at MarketWatch
12:10PM  Report: Prescription drug spending climbs in 2013 AP
11:49AM  J&J beats forecasts as strong sales of new drugs shine Reuters
11:17AM  J&J Earnings Beat Estimates As Pharma Sales Shine at Investor's Business Daily
10:58AM  Jim Cramer's Stop Trading: GILD KORS at TheStreet
10:55AM  Coca-Cola, Charles Schwab gain on quarterly results at MarketWatch
10:40AM  Stocks: Thin Gains; Yellen Coaxes Banks To Fortify at Investor's Business Daily
10:14AM  This strategy seems 'dumb as wood': Jim Cramer at CNBC
10:06AM  J&J beats forecasts, helped by new medicines at CNBC
09:40AM  Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo? at Motley Fool
09:04AM  [video] Cramer: Paying up when market rolled over 'true sin' at CNBC
09:02AM  [video] Cramer: Market rigged yesterday at CNBC
14-Apr-14 04:26PM  Gilead Sciences' Solvadi Is A Game Changer at Seeking Alpha
11:08AM  Stocks rally but this bull sees more pain ahead The Daily Ticker
10:46AM  Obamacare Enrollment: Quantity OK, Quality Questionable? at Motley Fool
10:30AM  Gilead Bucks Biotech Trend Thanks to Sovaldi News Zacks
10:30AM  Stocks Jump In Weak Trade at Investor's Business Daily
10:05AM  Momentum Investing: When Leaders Become Laggards at Barrons.com
08:38AM  Reevaluating Gilead Sciences After The Sell-Off at Seeking Alpha
08:07AM  Can Merck, Bristol-Myers, or AbbVie Compete with Gileads Cure for Hepatitis C? at Wall St. Cheat Sheet
07:59AM  Gilead Sovaldi should take majority share of HCV market, says Stifel theflyonthewall.com
05:57AM  Price of New Hepatitis C Drugs Not So Daunting After All at Bloomberg
13-Apr-14 04:04PM  Biotech Is Officially in a Bear Market. Is It Time to Panic? at Motley Fool
10:02AM  Drug groups step up race for new hepatitis C treatments at Financial Times
08:05AM  The Hepatitis C Cure Poised to "Break the Country" at Motley Fool
11-Apr-14 06:44PM  Is Gilead Sciences a Value Stock? at Barrons.com
04:33PM  US STOCKS-Nasdaq ends below 4,000 for first time since early Feb. Reuters
04:15PM  Encouraging Results on Gilead's Sovaldi Zacks
03:26PM  US STOCKS-Tech, growth stocks sink Wall Street at week's end Reuters
02:18PM  Is Gilead Sciences a Value Stock? at Barrons.com
01:58PM  Why Gilead Sciences (GILD) Stock Is Up Today at TheStreet
01:46PM  US STOCKS-Wall St down as biotechs, financials drag Reuters
12:22PM  Texas Medicaid holds off on proposed limits for Gilead hepatitis drug Reuters
08:58AM  Today's Biotech Stocks to Watch: AbbVie Inc., Enanta Pharmaceuticals Inc. and Gilead Sciences at Motley Fool
08:42AM  [video] Here's what's pushing biotech lower: Expert at CNBC
08:32AM  3 Biotech Companies That Look To Be Good Buys After A Pullback at Seeking Alpha
06:41AM  Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% Zacks
06:07AM  Morning MoneyBeat: Momentum Stocks Tumble Out of Favor at The Wall Street Journal
01:02AM  Gileads SovaldiĀ® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease Business Wire
01:00AM  Doctors welcome hepatitis C drug rivals, Gilead still leads Reuters
12:06AM  This is the make-or-break level for biotech Talking Numbers
10-Apr-14 08:04PM  Why Alexion Pharmaceuticals, Gilead Sciences, and Monster Beverage Corporation Are Todays 3 Worst Stocks at Motley Fool -7.32%
06:07PM  As Hep C Cure Rate Hits 98%, Merck Challenges Gilead Investor's Business Daily
05:05PM  Stocks Fall In Higher Volume; Alexion, Gilead Drop 7% at Investor's Business Daily
05:00PM  Nasdaq plunges 3%; Dow closes down 267 points at USA TODAY
04:18PM  Stocks crushed as previous days gains wiped out Hot Stock Minute
04:15PM  Nasdaq plunges 3%; Dow closes down 267 points at USA TODAY
04:14PM  Nasdaq Leads Broad Rout In Stock Market at Investor's Business Daily
03:39PM  Gilead Announces Encouraging Sovaldi Data Zacks
03:38PM  Biotech: Like Lambs to the Slaughter at Barrons.com
03:37PM  Biotech: Like Lambs to the Slaughter at Barrons.com
03:15PM  [video] 99% of Nasdaq 100 in the red at CNBC
03:03PM  'Very Volatile' Biotech, in Chart Form at The Wall Street Journal
02:53PM  [video] Hep C breakthrough at CNBC
02:33PM  Thursday Sector Laggards: Healthcare, Technology & Communications at Forbes
01:24PM  Emerging Markets Pay 1% of U.S. Price for Gilead Sovaldi at Bloomberg
01:09PM  Oh Biotech, You Are a Cruel Bitch at TheStreet
01:04PM  U.S. drug industry group defends price of Gilead hepatitis drug Reuters
12:45PM  Midday movers: Netflix, Tesla Motors, CBS & More at CNBC
12:01PM  [video] Stick with large caps: Trader at CNBC
11:48AM  Merck Hepatitis C Combo Scores 98% Cure Rate at Investor's Business Daily
11:42AM  Report claims Tamiflu, Relenza do little to prevent the spread of flu at theflyonthewall.com
11:33AM  Gilead Risks Beyond Just Merck: Serious Chart Violation Watch at 24/7 Wall St.
11:31AM  May 30th Options Now Available For Gilead Sciences (GILD) at TheStreet
10:46AM  Natco seeks to block Gilead's hepatitis C drug patent in India-source Reuters
10:36AM  Gilead Sciences: How Big a Threat is Merck? at Barrons.com
10:26AM  Gilead (GILD) Is Today's Roof Leaker Stock at TheStreet
08:46AM  Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Inc. at Motley Fool
08:22AM  3 Top-Ranked Biotech Stocks on the Rebound Zacks
06:00AM  Toss these investments as part of spring cleaning at MarketWatch
01:02AM  Gilead Announces Results from Study of SovaldiĀ® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy Business Wire
01:02AM  Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Business Wire
01:00AM  Merck Data Show Potent Rival to Gileads Hepatitis C Pill at Bloomberg
09-Apr-14 02:28PM  Price of hepatitis C drug attacked at Financial Times
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
MARTIN JOHN CChairman and CEOApr 01Sale73.26140,62510,302,0284,429,387Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
Cogan John FrancisDirectorMar 14Option Exercise14.3414,000200,72553,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Option Exercise16.4090,0001,475,550209,302Mar 18 01:36 PM
Cogan John FrancisDirectorMar 14Sale76.4414,0001,070,10139,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Sale75.8990,0006,829,705119,302Mar 18 01:36 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Option Exercise21.5816,728360,90745,290Mar 12 01:39 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Sale79.3216,7281,326,83328,562Mar 12 01:39 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Option Exercise21.5831,000668,825117,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Option Exercise8.01140,6251,125,7034,397,860Mar 05 02:51 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Sale81.8433,0002,700,68784,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Sale81.74140,62511,495,3264,257,235Mar 05 02:51 PM
Washington Robin LEVP, CFOFeb 28Option Exercise22.3030,600682,49080,432Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Option Exercise24.0099,0002,375,550114,842Mar 04 02:56 PM
Washington Robin LEVP, CFOFeb 28Sale83.6530,6002,559,63549,832Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Sale83.5599,0008,271,93515,842Mar 04 02:56 PM
MOORE NICHOLAS GDirectorFeb 26Option Exercise26.6220,000532,30020,000Feb 28 12:50 PM
MOORE NICHOLAS GDirectorFeb 26Sale84.0520,0001,681,0700Feb 28 12:50 PM
Washington Robin LEVP, CFOFeb 21Option Exercise23.605,000118,00054,832Feb 25 03:41 PM
Washington Robin LEVP, CFOFeb 21Sale83.245,000416,21849,832Feb 25 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Option Exercise22.0219,068419,78219,068Feb 21 02:32 PM
Washington Robin LEVP, CFOFeb 19Sale83.3696880,69249,832Feb 21 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Sale83.1219,0681,584,9900Feb 21 02:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Option Exercise14.5090,0001,305,225158,124Feb 19 02:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Sale81.3690,0007,322,22268,124Feb 19 02:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Option Exercise21.5816,728360,90731,861Feb 12 04:44 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Sale79.1016,7281,323,19815,133Feb 12 04:44 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Option Exercise21.5831,000668,825118,516Feb 05 06:34 PM
MARTIN JOHN CChairman and CEOFeb 03Option Exercise8.01140,6251,125,7034,396,892Feb 05 06:53 PM
MARTIN JOHN CChairman and CEOFeb 03Sale79.96140,62511,244,0894,256,267Feb 05 06:53 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Sale80.7833,0002,665,59385,516Feb 05 06:34 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Option Exercise16.40100,0001,639,500316,418Jan 27 08:07 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Sale81.44100,0008,144,150216,418Jan 27 08:07 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Option Exercise19.94120,0002,392,393152,938Jan 22 07:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Sale80.00120,0009,600,00032,938Jan 22 07:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Option Exercise14.5090,0001,305,22590,000Jan 16 02:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Sale74.2390,0006,681,1470Jan 16 02:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.11111,0002,121,519145,938Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise8.01140,6251,125,7034,197,746Jan 06 05:38 PM
Washington Robin LSVP, CFOJan 02Option Exercise22.4935,600800,49035,600Jan 06 05:39 PM
Washington Robin LSVP, CFOJan 02Sale75.0335,6002,671,2140Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Sale75.02140,62510,550,1804,057,121Jan 06 05:38 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale75.01113,0008,476,56432,938Jan 06 05:39 PM
YOUNG KEVINEVP, Commercial OperationsDec 20Option Exercise16.4075,0001,229,625236,840Dec 24 01:41 PM
YOUNG KEVINEVP, Commercial OperationsDec 20Sale74.1975,0005,564,453161,840Dec 24 01:41 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 16Option Exercise14.5090,0001,305,22590,000Dec 18 02:16 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 16Sale71.7590,0006,457,9410Dec 18 02:16 PM
MARTIN JOHN CChairman and CEODec 02Option Exercise7.63282,2422,154,2124,339,363Dec 04 03:55 PM
MARTIN JOHN CChairman and CEODec 02Sale74.26282,24220,960,6974,057,121Dec 04 03:55 PM
MILLIGAN JOHN FPresident and COONov 25Option Exercise7.8125,588199,954590,362Nov 26 06:20 PM
YOUNG KEVINEVP, Commercial OperationsNov 22Option Exercise16.4075,0001,229,625236,840Nov 25 03:25 PM
YOUNG KEVINEVP, Commercial OperationsNov 22Sale74.3475,0005,575,549161,840Nov 25 03:25 PM
MILLIGAN JOHN FPresident and COONov 21Option Exercise7.63395,6343,019,677960,408Nov 25 01:16 PM
MILLIGAN JOHN FPresident and COONov 21Sale71.57395,63428,316,396564,774Nov 25 01:16 PM
DAVIGNON ETIENNEDirectorNov 21Sale71.579,778699,7931,160,186Nov 25 03:13 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 14Option Exercise14.5090,0001,305,22590,000Nov 18 03:12 PM
MILLIGAN JOHN FPresident and COONov 14Option Exercise7.63395,6353,019,684960,409Nov 18 03:22 PM
MILLIGAN JOHN FPresident and COONov 14Sale68.86395,63527,242,833564,774Nov 18 03:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 14Sale68.8690,0006,197,2920Nov 18 03:12 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise7.63395,6353,019,684960,409Nov 12 12:44 PM
MILLIGAN JOHN FPresident and COONov 07Sale67.51395,63526,710,875564,774Nov 12 12:44 PM
Washington Robin LSVP, CFONov 06Sale68.632,869196,91022,826Nov 08 05:28 PM
Washington Robin LSVP, CFONov 05Option Exercise0.006,000028,826Nov 07 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsNov 01Option Exercise19.0926,000496,21068,938Nov 05 07:58 PM
MARTIN JOHN CChairman and CEONov 01Option Exercise7.63282,2422,154,2124,339,363Nov 05 08:14 PM
MARTIN JOHN CChairman and CEONov 01Sale70.83282,24219,990,2134,057,121Nov 05 08:14 PM
Alton Gregg HEVP, Corp & Med AffairsNov 01Sale70.7930,0002,123,70838,938Nov 05 07:58 PM
YOUNG KEVINEVP, Commercial OperationsOct 23Option Exercise16.4075,0001,229,625236,840Oct 25 05:09 PM
YOUNG KEVINEVP, Commercial OperationsOct 23Sale68.5675,0005,142,000161,840Oct 25 05:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 14Option Exercise14.5090,0001,305,2252,249,643Oct 16 06:05 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 14Sale62.5490,0005,628,1872,159,643Oct 16 06:05 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise17.5626,000456,55472,938Oct 03 04:11 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise7.63282,2422,154,2124,339,363Oct 03 04:10 PM
MARTIN JOHN CChairman and CEOOct 01Sale62.70282,24217,696,5454,057,121Oct 03 04:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale62.7530,0001,882,54942,938Oct 03 04:11 PM
Washington Robin LSVP, CFOSep 30Option Exercise22.4935,600800,49062,730Oct 02 05:58 PM
Washington Robin LSVP, CFOSep 30Sale63.2835,6002,252,91627,130Oct 02 05:58 PM
YOUNG KEVINEVP, Commercial OperationsSep 23Option Exercise15.35100,0001,534,558261,840Sep 25 06:21 PM
YOUNG KEVINEVP, Commercial OperationsSep 23Sale62.88100,0006,288,189161,840Sep 25 06:21 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 16Option Exercise14.5090,0001,305,2252,249,643Sep 18 04:38 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 16Sale63.1190,0005,679,9622,159,643Sep 18 04:38 PM
Alton Gregg HEVP, Corp & Med AffairsSep 03Option Exercise16.4026,000426,27076,938Sep 05 07:43 PM
MARTIN JOHN CChairman and CEOSep 03Option Exercise7.63282,2422,154,2124,339,363Sep 05 07:44 PM
MARTIN JOHN CChairman and CEOSep 03Sale60.97282,24217,209,4904,057,121Sep 05 07:44 PM
Alton Gregg HEVP, Corp & Med AffairsSep 03Sale60.9930,0001,829,66746,938Sep 05 07:43 PM
MOORE NICHOLAS GDirectorAug 30Option Exercise20.55151,7203,118,014151,720Sep 04 07:09 PM
MOORE NICHOLAS GDirectorAug 30Sale60.42151,7209,166,5830Sep 04 07:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOAug 14Option Exercise14.5090,0001,305,2252,249,643Aug 16 12:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOAug 14Sale58.7790,0005,288,8812,159,643Aug 16 12:22 PM
Cogan John FrancisDirectorAug 02Option Exercise10.9917,000186,87356,542Aug 05 04:12 PM